tiprankstipranks
CytoSorbents highlights new data to prevent endothelial damage to blood vessels
The Fly

CytoSorbents highlights new data to prevent endothelial damage to blood vessels

CytoSorbents announced its scientific program for the 42nd International Symposium on Intensive Care & Emergency Medicine or ISICEM 2023 Congress being held this week in Brussels, Belgium. Prof. Zsolt Molnar of Semmelweiss University, Budapest, Hungary and CytoSorbents Europe will summarize the growing body of pre-clinical and clinical data supporting the use of CytoSorb to prevent endothelial damage to blood vessels, one of the main factors leading to failure of the vascular system and capillary leak syndrome – direct causes of shock, acute respiratory distress syndrome ARDS , and tissue edema. Dr. Gabriella Bottari of Bambino Gesu Children’s Hospital, Rome, Italy, will present data from the latest retrospective observational study from 7 pediatric intensive care units in Italy, highlighting the positive impact of CytoSorb in managing septic shock in pediatric patients Dr. Christian Steiner, Executive Vice President of Sales and Marketing of CytoSorbents stated, "ISICEM – the biggest scientific and clinical conference on Intensive Care Medicine outside the United States – is an excellent opportunity to unveil the latest research results on CytoSorb. CytoSorb is being increasingly used as a ‘go-to’ therapy option for critically ill patients suffering from a broad range of life-threatening illnesses, especially septic shock. Treating physicians and health care professionals around the world have directly experienced the beneficial impact of our therapy on their patients. With the important new data to be presented at our symposia, we now add to the significant body of evidence that helps to explain how our CytoSorb therapy works, underscoring the multiple mechanisms of action through which it has its biological and physiological effects. The contribution of CytoSorb in helping to effectively stabilize and manage critically ill patients is becoming clearer, particularly when patient selection, timing, and dosing are appropriate. We are grateful to the many international clinicians and scientists who have relentlessly contributed to the development of this therapy, and we are proud to have a role in helping to save patient lives."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on CTSO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles